The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

Despite the muted success of Sanofi's Dengvaxia in the global market, Globaldata analysts forecast a rosy outlook for Qdenga.

CastleVax, a clinical-stage biotechnology company developing intranasal vaccines using its attenuated Newcastle Disease Virus (NDV)-based vaccine platform, announced today that the first participant ...

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full ...

Findings from a phase 3 trial show Qdenga, Takeda's live-attenuated dengue vaccine, provided 61.2% vaccine efficacy against ...

Indonesia's Food and Drug Monitoring Agency (BPOM) revealed that 23 illegal cosmetics products contained harmful chemicals ...